<DOC>
	<DOCNO>NCT00077077</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , DJ-927 capecitabine , use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : This phase I trial study side effect best dose DJ-927 capecitabine treat patient locally advance metastatic solid tumor .</brief_summary>
	<brief_title>DJ-927 Capecitabine Treating Patients With Locally Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose DJ-927 capecitabine patient locally advance metastatic solid tumor . - Determine dose-limiting non-dose-limiting toxic effect regimen patient . Secondary - Determine toxicity profile regimen patient . - Determine possible pharmacokinetic interaction regimen patient . - Determine antitumor activity regimen patient . OUTLINE : This open-label , dose-escalation , nonrandomized , multicenter study . - Course 1 : Patients receive oral DJ-927 day 1 oral capecitabine day 0 1 twice daily day 2-14 . - Course 2 : Patients receive DJ-927 course 1 oral capecitabine twice daily day 2-15 . - Course 3 subsequent course : Patients receive DJ-927 course 1 oral capecitabine twice daily day 1-14 . All course repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos DJ-927 capecitabine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . A minimum 6 patient receive treatment MTD . Patients follow every 3 month . PROJECTED ACCRUAL : A total 30-40 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor Locally advance metastatic disease Minimally pretreated No symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic SGOT SGPT great 2.5 time upper limit normal ( ULN ) ( 5 time ULN liver metastasis present ) Bilirubin great 1.5 time ULN Renal Creatinine great 1.5 time ULN Gastrointestinal No prior chronic diarrhea No swallow and/or malabsorption problem No diarrhea ( excess 23 stools/day normal frequency past month ) Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No prior severe lifethreatening hypersensitivity reaction taxane capecitabine No concurrent serious infection No neuropathy grade 2 great No malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ cervix No severe uncontrolled underlying medical disease would preclude study participation No psychiatric disorder would preclude give informed consent study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent anticancer biologic therapy Chemotherapy Recovered prior chemotherapy No concurrent anticancer chemotherapy Endocrine therapy Not specify Radiotherapy Recovered prior radiotherapy No concurrent anticancer radiotherapy Concurrent localize radiotherapy nonindicator lesion pain relief allow provide method pain control ineffective Surgery At least 4 week since prior major surgery recover No prior major surgery stomach small intestine Other At least 4 week since prior myelosuppressive therapy More 28 day since prior investigational drug ( include analgesic and/or antiemetic ) No concurrent anticancer therapy No concurrent anticancer cytotoxic therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>